Show simple item record

dc.contributor.authorWeider, T
dc.contributor.authorRichardson, SJ
dc.contributor.authorMorgan, NG
dc.contributor.authorPaulsen, TH
dc.contributor.authorDahl-Jørgensen, K
dc.contributor.authorHammerstad, SS
dc.date.accessioned2021-02-10T15:56:34Z
dc.date.issued2020-12-25
dc.description.abstractCONTEXT: The origin of Graves' disease (GD) remains elusive. However, evidence of an association between GD and viral infections is emerging. Human leukocyte antigen (HLA) class I presents viral antigens to circulating immune cells and plays a crucial role in the defense against viral infections. OBJECTIVE: To investigate HLA class I expression, enterovirus presence and the viral immune response proteins signal transducer and activation of transcription 1 (STAT1) and protein kinase R (PKR) in thyroid tissue from GD patients. DESIGN AND PATIENTS: We collected thyroid tissue from core needle biopsies or surgical specimens from 48 GD patients and 24 controls. Standard immunohistochemistry was used to detect HLA class I and enteroviral capsid protein 1 (VP1) on formalin-fixed and paraffin-embedded tissue. STAT1 and PKR were examined by combined immunofluorescence staining. MAIN OUTCOME MEASURES: HLA class I expression score. RESULTS: The HLA class I expression score, which takes both proportion and intensity of immunostaining into account, was significantly higher in GDs (3.1±3.3) than in controls (0.5±0.9) (p<0.001). Significantly more VP1 positive thyroid cells were found GD samples (50.1± 30.5%) than in controls (14.9±10.5%) (p<0.001). STAT1 and HLA class I was found within the same thyroid cells and PKR and VP1 were also colocalized within thyroid cells. CONCLUSION: HLA class I is upregulated in GD and enterovirus protein is prevalent in thyroid tissue. The colocalization of HLA class I with STAT1 and VP1 with PKR indicates an antiviral tissue response. These findings support the concept of a link between viral infections and GD.en_GB
dc.description.sponsorshipEuropean Union FP7(FP7/2007-2013)en_GB
dc.description.sponsorshipSouth-Eastern Norway Regional Health Authority (Helse Sør-Øst)
dc.description.sponsorshipUniversity of Oslo
dc.description.sponsorshipDiabetes Research Foundation
dc.identifier.citationPublished online 25 December 2020en_GB
dc.identifier.doi10.1210/clinem/dgaa958
dc.identifier.grantnumber261441en_GB
dc.identifier.grantnumber2017024
dc.identifier.grantnumber5-CDA-2014-221-A-N
dc.identifier.other6047595
dc.identifier.urihttp://hdl.handle.net/10871/124667
dc.language.isoenen_GB
dc.publisherOxford University Press / Endocrine Societyen_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/33367784en_GB
dc.rights© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.comen_GB
dc.subjectGraves’ diseaseen_GB
dc.subjectHLA class Ien_GB
dc.subjectSTAT1en_GB
dc.subjectautoimmune thyroid diseaseen_GB
dc.subjectenterovirusen_GB
dc.subjectviral infectionsen_GB
dc.titleHLA class I upregulation and antiviral immune responses in Graves' diseaseen_GB
dc.typeArticleen_GB
dc.date.available2021-02-10T15:56:34Z
dc.identifier.issn0021-972X
exeter.place-of-publicationUnited Statesen_GB
dc.descriptionThis is the final version. Available on open access from Oxford University Press via the DOI in this record. en_GB
dc.descriptionData Availability: Restrictions apply to some or all the availability of data generated or analyzed during this study to preserve patient confidentiality. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided.
dc.identifier.eissn1945-7197
dc.identifier.journalJournal of Clinical Endocrinology and Metabolismen_GB
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_GB
dcterms.dateAccepted2020-12-18
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2020-12-25
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2021-02-10T15:53:09Z
refterms.versionFCDVoR
refterms.dateFOA2021-02-10T15:56:46Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Except where otherwise noted, this item's licence is described as © The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com